1.35  0.05 (3.85%)		11-26 16:00
Open: 1.3361 High: 1.35 Volume: 1,255		Pre. Close: 1.3 Low: 1.31 Market Cap: 74(M)

Short term
Mid term
Targets	6-month :	1.67	1-year :	1.77
Resists	First :	1.43	Second :	1.51
Pivot price	1.35
Supports	First :	1.28	Second :	1.07
MAs	MA(5) :	1.31	MA(20) :	1.36
	MA(100) :	1.51	MA(250) :	1.52
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	19	D(3) :	10.4
RSI	RSI(14): 44.5
52-week	High :	1.78	Low :	1.22

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ INCR ] has closed above bottom band by 49.5%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.37 - 1.37	1.37 - 1.38
Low:	1.3 - 1.3	1.3 - 1.31
Close:	1.34 - 1.35	1.35 - 1.36

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

Mon, 03 Nov 2025
InterCure (NASDAQ: INCR) signs Cannasoul collaboration; 28% stake, path to 51% - Stock Titan

Mon, 03 Nov 2025
InterCure and Cannasoul Sign Strategic Investment and - GlobeNewswire

Wed, 08 Oct 2025
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow - Yahoo Finance

Fri, 19 Sep 2025
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands - GlobeNewswire

Thu, 01 May 2025
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PR Newswire

Wed, 12 Feb 2025
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	55 (M)
Shares Float	36 (M)
Held by Insiders	26 (%)
Held by Institutions	3.9 (%)
Shares Short	4 (K)
Shares Short P.Month	24 (K)

EPS	-0.48
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.59
Profit Margin	-29.2 %
Operating Margin	4.4 %
Return on Assets (ttm)	-7.8 %
Return on Equity (ttm)	-16.7 %
Qtrly Rev. Growth	3.4 %
Gross Profit (p.s.)	0.74
Sales Per Share	4.46
EBITDA (p.s.)	-1.48
Qtrly Earnings Growth	0 %
Operating Cash Flow	-11 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	-2.82
PEG Ratio	0
Price to Book value	0.17
Price to Sales	0.3
Price to Cash Flow	-6.55

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.